Brief observationThe effect of self monitoring of blood glucose concentrations on glycated hemoglobin levels in diabetic patients not taking insulin: A blinded, randomized trial
Section snippets
Methods
All type 2 diabetic patients not taking insulin who were either currently enrolled or on entrance into the DMCP were approached to enter the study. All 89 patients consented and were randomized. One patient did not return after being randomized to see the nurse or the dietitian (who provided nutritional counseling to all patients enrolled in the DMCP) and was not included in the study. All patients were followed for 6 months. Patients were instructed to measure glucose levels before and between
Results
There were no differences in the baseline characteristics of the patients randomized to the monitoring group and those who were randomized to the control group (Table 1). Patients in the monitoring group averaged 4.0 ± 1.0 dietary visits compared with 3.2 ± 0.9 visits in the control group. The average number of tests in patients who monitored was 129. There were no changes in weight or body mass index during the study in either group (Table 2). Medications at the end of the study were similar
Discussion
The results of this randomized, single blind study in type 2 diabetic patients not taking insulin failed to demonstrate lower A1C levels in those that perform pre- and postprandial glucose testing. This lack of an effect is consistent with 11 other studies as well as a meta-analysis of 6 of the randomized ones.22 Four studies did show an effect. In one,17 a “therapy decision scheme” was applied only to the group that tested but not to the control group, casting doubt on whether testing per se
Acknowledgments
The authors gratefully acknowledge Lifescan, Inc., for donating glucose meters and strips and the statistical help of Mohsen Bazargan, PhD.
References (22)
- et al.
Glycemic control in diabetes mellitushave changes in therapy made a difference?
Am J Med
(1996) - et al.
Self-monitoring of blood glucose levels and glycemic controlthe Northern California Kaiser Permanente Diabetes Registry
Am J Med
(2001) - et al.
Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitusa randomized prospective 6-year study
Diabetes Res Clin Pract
(1995) - et al.
Does self-monitoring of blood glucose levels improve dietary compliance for obese patients with type 2 diabetes?
Am J Med
(1986) - et al.
Reliability of self-monitoring of blood glucose by CSII-treated patients with type 1 diabetes
Diabetes Care
(1989) - et al.
Is glucose self-monitoring beneficial in non-insulin-treated diabetic patients? Results of a randomized comparative trial
Diabetes Metab
(1989) - et al.
Glycated hemoglobin and related factors in diabetic children and adolescents under 18 years of agea Belgian experience
Diabetes Care
(1997) - et al.
Improved glycemic control in intensively treated type1 diabetic patients using blood glucose meters with storage capability and computer-assisted analyses
Diabetes Care
(1998) - et al.
Frequency of blood glucose monitoring in relation to glycemic controlobservational study with diabetes database
BMJ
(1999) - et al.
The impact of blood glucose self-monitoring on metabolic control and quality of life in type 2 diabetic patientsan urgent need for better educational strategies
Diabetes Care
(2001)
Impact of glucose self-monitoring on glycohemoglobin values in a veteran population
Arch Intern Med
Cited by (156)
Self-monitoring blood glucose improves glycemic control in type 2 diabetes without intensive treatment: A systematic review and meta-analysis
2018, Diabetes Research and Clinical PracticeMonitoring Glycemic Control
2018, Canadian Journal of DiabetesTrends in Blood Glucose Test Strip Utilization: A Population-Wide Analysis in Saskatchewan, Canada
2018, Canadian Journal of DiabetesOpportunity Cost and Policy: A Utilization Review of Self-monitoring of Blood Glucose in Manitoba, Canada
2016, Clinical Therapeutics
This study was supported by grants from Eli Lilly and Company and the NIH (DK 54047).